<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03288597</url>
  </required_header>
  <id_info>
    <org_study_id>68Ga&amp;FDG PET/CT</org_study_id>
    <nct_id>NCT03288597</nct_id>
  </id_info>
  <brief_title>Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms</brief_title>
  <official_title>A Prospective Exploration in the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      68Ga-DOTANOC and 18F-FDG PET/CT have important values in the staging and clinical treatment
      of neuroendocrine tumors. Retrospective studies suggest that the positivite rates and SUVmax
      of dual imaging associated with pathological findings and prognosis. The study was designed
      to confirm thet clinical values of dual imagings for neuroendocrine tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>The correlation between the positive rate and SUVs of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT and treatment response</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The correlation between positive rate and SUV of PET/CT and prognosis</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare SUVmax, tumor/liver ratio as a prognostic marker</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>A: advanced and metastatic neuroendocrine tumors</arm_group_label>
    <description>Advanced and metastatic neuroendocrine tumors receive syestematic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A: advanced and metastatic neuroendocrine carcinomas</arm_group_label>
    <description>Advanced and metastatic neuroendocrine carcinomas receive syestematic treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NET</intervention_name>
    <description>At the beginning of the treatment with SSA, after 6 months, 12 months, or chemotherapy, after 3 months or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT</description>
    <arm_group_label>A: advanced and metastatic neuroendocrine tumors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NEC</intervention_name>
    <description>At the beginning of the treatment with chemotherapy 4-6 cycles or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT</description>
    <arm_group_label>A: advanced and metastatic neuroendocrine carcinomas</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Neuroendocrine neoplasmes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. sign written informed consent form

          2. age ≥ 18 years

          3. pathologically confirmed neuroendocrine, Ki67&gt;=10%;

          4. ECOG 0-1;

          5. No prior antitumor treatment with chemotherapy targeting regimens for neuroendocrine
             carcimomas, no more than 2 systematic treatment for neuroendocrine tumors;

          6. Unresectable disease;

          7. At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded)
             (routine CT scan &gt;=20mm, spiral CT scan &gt;=10mm, no prior radiation to measurable
             lesions);

          8. Predicted survival &gt;=3 months;

          9. Negative serum or urine pregnant test within 7 days prior to randomization for
             child-bearing age women;

         10. Sexually active males or females willing to practice contraception during the study
             until 30 days after end of study.

        Exclusion Criteria:

          1. In the process of antitumor therapy with effective response;

          2. Refuse to accept PET/CT;

          3. Pregnant or nursing, or sexually active males or females refuse to practice
             contraception during the study until 30 days after end of study;

          4. Person with no capacity (legally) or inappropriate to continue study treatment for
             ethics/medical reasons；
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lin Shen, Professor</last_name>
    <phone>01088196561</phone>
    <email>linshenpku@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shen Lin, Professor</last_name>
      <phone>010-88196561</phone>
      <email>Linshenpku@163.com</email>
    </contact>
    <investigator>
      <last_name>Shen Lin, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2017</study_first_submitted>
  <study_first_submitted_qc>September 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2017</study_first_posted>
  <last_update_submitted>September 16, 2017</last_update_submitted>
  <last_update_submitted_qc>September 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>MD, Professor, Chief of Department of GI Oncology, Peking University Cancer Hospital</investigator_title>
  </responsible_party>
  <keyword>positive rate</keyword>
  <keyword>SUVmax</keyword>
  <keyword>relationship</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

